{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T16:44:34Z","timestamp":1788799474150,"version":"build-2803163510"},"reference-count":35,"publisher":"BMJ","issue":"4","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2024,3,24]]},"published-print":{"date-parts":[[2024,4]]},"abstract":"<jats:p>A man in his late 60s with a history of well-controlled type 2 diabetes and hepatic cirrhosis presented to the emergency department due to uncontrollable hyperglycaemia following the initial brentuximab vedotin (BV) infusion. BV was initiated as a treatment for mycosis fungoides, a form of cutaneous T-cell lymphoma. The patient was diagnosed with severe hyperglycaemia with ketosis. Empiric treatment with amoxicillin-clavulanic acid, hydration and intravenous insulin infusion was initiated. Hyperglycaemia persisted despite receiving massive amounts of insulin and was corrected only after treatment with high-dose methylprednisolone for suspected type B insulin resistance. Extremely high and difficult-to-treat hyperglycaemia is a rare side effect of BV. Unfortunately, the patient died of upper gastrointestinal bleeding 22 days after discharge. In patients with obesity and\/or diabetes mellitus, the blood glucose levels should be carefully monitored when treated with BV.<\/jats:p>","DOI":"10.1136\/bcr-2022-251867","type":"journal-article","created":{"date-parts":[[2024,4,3]],"date-time":"2024-04-03T01:55:16Z","timestamp":1712109316000},"page":"e251867","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":5,"title":["Severe insulin resistance in a patient with diabetes after treatment with brentuximab vedotin"],"prefix":"10.1136","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8990-6236","authenticated-orcid":false,"given":"Greet","family":"Peeters","sequence":"first","affiliation":[{"name":"Endocrinology-Diabetology, ZNA Jan Palfijn, Merksem, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Verhaegen","sequence":"additional","affiliation":[{"name":"Endocrinology-Diabetology, ZNA Jan Palfijn, Merksem, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2024,4,2]]},"reference":[{"key":"2025082723525080000_17.4.e251867.1","article-title":"Interventions for mycosis fungoides","volume":"7","author":"Valipour","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"2025082723525080000_17.4.e251867.2","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1002\/ajh.25577","article-title":"Mycosis fungoides and S\u00e9zary syndrome: 2019 update on diagnosis, risk-stratification, and management","volume":"94","author":"Hristov","year":"2019","journal-title":"Am J Hematol"},{"key":"2025082723525080000_17.4.e251867.3","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1111\/bjd.20588","article-title":"Multicentric EORTC retrospective study shows efficacy of brentuximab vedotin in patients who have mycosis fungoides and S\u00e9zary syndrome with variable CD30 positivity","volume":"185","author":"Papadavid","year":"2021","journal-title":"Br J Dermatol"},{"key":"2025082723525080000_17.4.e251867.4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31266-7"},{"key":"2025082723525080000_17.4.e251867.5","doi-asserted-by":"publisher","DOI":"10.4161\/mabs.20230"},{"key":"2025082723525080000_17.4.e251867.6","first-page":"e98","article-title":"Severe insulin resistance with diabetic ketoacidosis after brentuximab treatment","volume":"6","author":"Chiang","year":"2020","journal-title":"AACE Clin Case Rep"},{"key":"2025082723525080000_17.4.e251867.7","doi-asserted-by":"crossref","DOI":"10.1007\/s11864-020-00809-w","article-title":"Mycosis fungoides and S\u00e9zary syndrome: updates and review of current therapy","volume":"22","author":"Kamijo","year":"2021","journal-title":"Curr Treat Options Oncol"},{"key":"2025082723525080000_17.4.e251867.8","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ejca.2017.02.027","article-title":"European organisation for research and treatment of cancer consensus recommendations for the treatment of mycosis fungoides\/S\u00e9zary syndrome - update 2017","volume":"77","author":"Trautinger","year":"2017","journal-title":"Eur J Cancer"},{"key":"2025082723525080000_17.4.e251867.9","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32984-2"},{"key":"2025082723525080000_17.4.e251867.10","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-12-397893"},{"key":"2025082723525080000_17.4.e251867.11","doi-asserted-by":"crossref","first-page":"SUN","DOI":"10.1210\/js.2019-SUN-174","article-title":"SUN-174 severe insulin resistance and diabetic ketoacidosis after brentuximab vendotin and cyclosporin treatment","volume":"3","author":"Lee","year":"2019","journal-title":"J Endocr Soc"},{"key":"2025082723525080000_17.4.e251867.12","doi-asserted-by":"crossref","first-page":"e660","DOI":"10.1016\/S2352-3026(20)30221-0","article-title":"Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1\/2 trial","volume":"7","author":"Diefenbach","year":"2020","journal-title":"Lancet Haematol"},{"key":"2025082723525080000_17.4.e251867.13","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1007\/s13410-022-01116-w","article-title":"Brentuximab vedotin-associated diabetic ketoacidosis: a case report","volume":"43","author":"K\u00f6ksalan","year":"2023","journal-title":"Int J Diabetes Dev Ctries"},{"key":"2025082723525080000_17.4.e251867.14","article-title":"Diabetic ketoacidosis and profound insulin resistance from brentuximab vedotin","volume":"15","author":"Thakkar","year":"2023","journal-title":"Cureus"},{"key":"2025082723525080000_17.4.e251867.15","doi-asserted-by":"crossref","unstructured":"Quintas J , Mowatt KB , Mullally JA , et al . New-onset persistent hyperglycemia with initiation of brentuximab treatment. J Oncol Pharm Pract 2023;10781552231168951. doi:10.1177\/10781552231168951","DOI":"10.1177\/10781552231168951"},{"key":"2025082723525080000_17.4.e251867.16","first-page":"337","article-title":"Type B insulin resistance syndrome: a systematic review","volume":"64","author":"Martins","year":"2020","journal-title":"Arch Endocrinol Metab"},{"key":"2025082723525080000_17.4.e251867.17","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.313.7069.1385"},{"key":"2025082723525080000_17.4.e251867.18","doi-asserted-by":"crossref","first-page":"175672","DOI":"10.1016\/j.ejphar.2023.175672","article-title":"Effects of statin therapy on glycemic control and insulin resistance: a systematic review and meta-analysis","volume":"947","author":"Alvarez-Jimenez","year":"2023","journal-title":"Eur J Pharmacol"},{"key":"2025082723525080000_17.4.e251867.19","doi-asserted-by":"publisher","DOI":"10.1186\/cc9100"},{"key":"2025082723525080000_17.4.e251867.20","doi-asserted-by":"publisher","DOI":"10.1038\/ncpendmet0071"},{"key":"2025082723525080000_17.4.e251867.21","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22020623","article-title":"Molecular mechanisms of glucocorticoid-induced insulin resistance","volume":"22","author":"Beaupere","year":"2021","journal-title":"Int J Mol Sci"},{"key":"2025082723525080000_17.4.e251867.22","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.24.1.131"},{"key":"2025082723525080000_17.4.e251867.23","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1042\/CS20200022","article-title":"Cirrhosis and insulin resistance: current knowledge, pathophysiological mechanisms, complications and potential treatments","volume":"134","author":"Clarembeau","year":"2020","journal-title":"Clin Sci (Lond)"},{"key":"2025082723525080000_17.4.e251867.24","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.aohep.2020.04.010","article-title":"Spontaneous bacterial peritonitis and extraperitoneal infections in patients with cirrhosis","volume":"19","author":"Mattos","year":"2020","journal-title":"Ann Hepatol"},{"key":"2025082723525080000_17.4.e251867.25","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2011-1159"},{"key":"2025082723525080000_17.4.e251867.26","doi-asserted-by":"publisher","DOI":"10.1210\/er.2010-0020"},{"key":"2025082723525080000_17.4.e251867.27","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-022-01766-4"},{"key":"2025082723525080000_17.4.e251867.28","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21626"},{"key":"2025082723525080000_17.4.e251867.29","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2020.2948","article-title":"Diabetes, weight change, and pancreatic cancer risk","volume":"6","author":"Yuan","year":"2020","journal-title":"JAMA Oncol"},{"key":"2025082723525080000_17.4.e251867.30","doi-asserted-by":"crossref","DOI":"10.3390\/metabo12111103","article-title":"Impact of diabetes mellitus in patients with pancreatic neuro-endocrine tumors: causes, consequences, and future perspectives","volume":"12","author":"Hernandez-Rienda","year":"2022","journal-title":"Metabolites"},{"key":"2025082723525080000_17.4.e251867.31","unstructured":"Adcetris. Available: https:\/\/adcetrispro.com\/previously-untreated-stage-III-IV-classical-hodgkin-lymphoma [Accessed 11 Sep 2023]."},{"key":"2025082723525080000_17.4.e251867.32","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1002965"},{"key":"2025082723525080000_17.4.e251867.33","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1111\/ejh.12396","article-title":"Severe cytokine release syndrome after the first dose of Brentuximab Vedotin in a patient with relapsed systemic anaplastic large cell lymphoma (sALCL): a case report and review of literature","volume":"94","author":"Alig","year":"2015","journal-title":"Eur J Haematol"},{"key":"2025082723525080000_17.4.e251867.34","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2249.2003.02223.x"},{"key":"2025082723525080000_17.4.e251867.35","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.2006.03307.x"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2022-251867","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T06:52:59Z","timestamp":1756363979000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2022-251867"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":35,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,4,2]]},"published-print":{"date-parts":[[2024,4]]}},"alternative-id":["10.1136\/bcr-2022-251867"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2022-251867","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4]]}}}